The 8 most recent market catalysts affecting $BLSM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 55
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
Leerink Partners, a prominent investment bank, has maintained its 'Outperform' rating on BlossomHill Therapeutics and raised its price target from $36 to $40. This action signals c…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
Guggenheim analyst Michael Schmitz maintained a 'Buy' rating on BlossomHill Therapeutics and raised the price target from $30 to $40. This action signals increased confidence from …
Sep 18, 2026
Corporate Catalyst
Bearish
Impact 92
BlossomHill Therapeutics Q2 EPS $(8.75)
BlossomHill Therapeutics (BLSM) announced Q2 EPS of $(8.75), representing a substantial 58.8% increase in losses year-over-year. This significant deterioration in financial perform…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 65
LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32
LifeSci Capital has initiated coverage on BlossomHill Therapeutics (BLSM) with an 'Outperform' rating and a $32 price target. This event is significant because new analyst coverage…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36
Leerink Partners has initiated coverage on BlossomHill Therapeutics (BLSM) with an 'Outperform' rating and a $36 price target. This is a significant event for a relatively new or l…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 75
JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28
JP Morgan analyst Brian Cheng has initiated coverage on BlossomHill Therapeutics (BLSM) with an 'Overweight' rating and a $28 price target. This event is significant because new an…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 75
Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30
Guggenheim's initiation of coverage on BlossomHill Therapeutics (BLSM) with a 'Buy' rating and a $30 price target is a significant event for the company. Analyst coverage, especial…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 65
HC Wainwright & Co. Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $35
HC Wainwright & Co. analyst Robert Burns has initiated coverage on BlossomHill Therapeutics (BLSM) with a 'Buy' rating and a $35 price target. This is a positive development for th…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.